Abstract 400P
Background
Second- (afatinib and dacomitinib) and third-generation (osimertinib) EGFR tyrosine kinase inhibitors (TKIs) have demonstrated superior efficacy versus the first-generation EGFR TKIs (erlotinib and gefitinib) for EGFRm+ NSCLC. However, TKI resistance is inevitable and up to 75% of afatinib-treated patients develop the T790M mutation. Hence, questions remain about the optimal sequence of EGFR TKIs. The observational GioTag study investigated outcomes in patients with EGFRm+ NSCLC treated with sequential afatinib and osimertinib in a ‘real-world’ setting. Time to treatment failure (TTF) and overall survival (OS) were encouraging (Hochmair et al Future Oncol 2019). Here, we report final TTF and OS data for Asian patients.
Methods
Data were retrospectively collected for patients with EGFRm+ (Del19, L858R) NSCLC who had T790M+ disease after first-line afatinib and then received osimertinib. TTF was the primary outcome; OS analysis was exploratory.
Results
203 patients were included in the global GioTag study; of these, 50 were Asian. After a median follow-up of 33.9 months, median TTF was 37.1 months (90% CI: 28.1–40.3) and median OS was 44.8 months (90% CI: 37.0–57.8) in Asian patients (overall global study population: median TTF 27.7 months [90% CI: 26.7–29.9], median OS 37.6 months [90% CI: 35.5–41.3]). Clinical benefit was particularly encouraging in Asian patients with Del19-positive disease (n=31): median TTF 40.0 months (90% CI: 36.4–45.0), median OS 45.7 months (90% CI: 38.2–57.8). Median TTF and OS were 38.2 months (90%: 28.9–40.3) and 44.8 months (90% CI: 38.2–57.8), respectively, in Asian patients who received a starting dose of afatinib 40 mg (n=46), and 36.4 months (90% CI: 28.1–41.7) and 41.3 months (90% CI: 36.9–57.8), respectively, in Asian patients with ECOG performance status 0/1 (n=45).
Conclusions
In a real-world clinical practice setting, sequential afatinib and osimertinib is effective, particularly in Asian patients with EGFRm+ NSCLC who develop T790M. Median OS was nearly 4 years in those with Del19+ disease, suggesting sequential TKI use could potentially allow these patients to receive long-term chemotherapy-free treatment.
Clinical trial identification
NCT03370770.
Editorial acknowledgement
Medical writing assistance, supported financially by Boehringer Ingelheim, was provided by Jane Saunders, of GeoMed, an Ashfield company, part of UDG Healthcare plc.
Legal entity responsible for the study
Boehringer Ingelheim.
Funding
Boehringer Ingelheim.
Disclosure
M.J. Hochmair: Advisory/Consultancy, Speaker Bureau/Expert testimony: AstraZeneca; Advisory/Consultancy, Speaker Bureau/Expert testimony: BMS; Advisory/Consultancy, Speaker Bureau/Expert testimony: Boehringer Ingelheim; Advisory/Consultancy, Speaker Bureau/Expert testimony: MSD; Advisory/Consultancy, Speaker Bureau/Expert testimony: Takeda. A. Morabito: Honoraria (self): Roche; Honoraria (self): AstraZeneca; Honoraria (self): Pfizer; Honoraria (self): Boehringer Ingelheim; Honoraria (self): Takeda; Honoraria (self): BMS; Honoraria (self): MSD. D. Hao: Advisory/Consultancy: Roche; Honoraria (self), Research grant/Funding (self): AstraZeneca; Research grant/Funding (self), Travel/Accommodation/Expenses: Boehringer Ingelheim. C-T. Yang: Advisory/Consultancy: BI; Advisory/Consultancy: MSD; Advisory/Consultancy: Ono; Advisory/Consultancy: Chugai; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Pfizer. R.A. Soo: Honoraria (self), Research grant/Funding (self): AstraZeneca; Honoraria (self), Research grant/Funding (self): Boehringer Ingelheim; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Eli Lilly; Honoraria (self): Merck; Honoraria (self): Novartis; Honoraria (self): Pfizer; Honoraria (self): Roche; Honoraria (self): Taiho; Honoraria (self): Takeda; Honoraria (self): Yuhan; Honoraria (self): Amgen. J.C-H. Yang: Honoraria (institution), Advisory/Consultancy: Boehringer Ingelheim; Honoraria (institution), Advisory/Consultancy: Novartis; Honoraria (institution), Advisory/Consultancy: AstraZeneca; Honoraria (institution), Advisory/Consultancy: Roche/Genentech; Honoraria (institution), Advisory/Consultancy: Lilly; Honoraria (institution), Advisory/Consultancy: MSD Oncology; Honoraria (institution), Advisory/Consultancy: Merck Sernono; Honoraria (institution), Advisory/Consultancy: Celgene; Honoraria (institution), Advisory/Consultancy: Bayer; Honoraria (institution), Advisory/Consultancy: Pfizer; Honoraria (institution), Advisory/Consultancy: Ono Pharmaceutical; Honoraria (institution), Advisory/Consultancy: Bristol-Myers Squibb; Honoraria (institution), Advisory/Consultancy: Yuhan; Honoraria (institution), Advisory/Consultancy: Hansoh; Honoraria (institution), Advisory/Consultancy: Brueprint Medicines; Honoraria (institution), Advisory/Consultancy: Daiichi Snakyo; Honoraria (institution), Advisory/Consultancy: Amgen; Honoraria (institution), Advisory/Consultancy: Takeda Oncology; Honoraria (institution), Advisory/Consultancy: Incyte; Honoraria (institution), Advisory/Consultancy: Boehringer Ingelheim; Roche; MSD; AstraZeneca; Novartis; Bristol-Myers Squibb; Ono Pharmaceutical; Takeda Oncology; Eli Lilly; Pfizer. B. Halmos: Advisory/Consultancy, Research grant/Funding (self): Merck; Advisory/Consultancy, Research grant/Funding (self): Novartis; Advisory/Consultancy, Research grant/Funding (self): Pfizer; Advisory/Consultancy, Research grant/Funding (self): Astra-Zeneca; Advisory/Consultancy, Research grant/Funding (self): Boehringer Ingelheim; Advisory/Consultancy: Spectrum; Advisory/Consultancy, Research grant/Funding (self): Takeda; Advisory/Consultancy, Research grant/Funding (self): BMS; Advisory/Consultancy, Research grant/Funding (self): Amgen; Advisory/Consultancy, Research grant/Funding (self): Guardant Health; Advisory/Consultancy: Foundation One; Advisory/Consultancy: TPT; Research grant/Funding (self): Eli-Lilly; Research grant/Funding (self): GSK; Research grant/Funding (self): Mirati; Research grant/Funding (self): AbbVie. A. Märten: Full/Part-time employment: Boehringer Ingelheim. T. Cufer: Advisory/Consultancy, Speaker Bureau/Expert testimony: AstraZeneca; Advisory/Consultancy, Speaker Bureau/Expert testimony: Boehringer Ingelheim; Advisory/Consultancy, Speaker Bureau/Expert testimony: Bristol-Myers Squibb; Advisory/Consultancy, Speaker Bureau/Expert testimony: Roche; Advisory/Consultancy, Speaker Bureau/Expert testimony: MSD; Advisory/Consultancy, Speaker Bureau/Expert testimony: Pfizer; Advisory/Consultancy, Speaker Bureau/Expert testimony: Takeda. All other authors have declared no conflicts of interest.
Resources from the same session
77P - Dual targeting oxidative phosphorylation and glycolysis in triple-negative breast cancers: En route to effective inhibition of tumour metabolism
Presenter: Alexander Scherbakov
Session: e-Poster Display Session
78P - Novel allogeneic cell immunotherapy for advanced cancers
Presenter: Ratnavelu Kananathan
Session: e-Poster Display Session
86P - The impact of sarcopenia on chemotherapy toxicity and survival rate among colorectal cancer patients who underwent chemotherapy: A systematic review and meta-analysis
Presenter: Timotius Hariyanto
Session: e-Poster Display Session
87P - Predictive risk factors and online nomograms for colon cancer with synchronous liver metastasis
Presenter: Yajuan Zhu
Session: e-Poster Display Session
88P - Research of radiomics based on indeterminate lung nodules predicting prognosis of LARC patients
Presenter: Zhang Zhiyuan
Session: e-Poster Display Session
89P - Biomarker analysis of regorafenib dose escalation study (RECC study): A phase II multicenter clinical trial in Japan
Presenter: Masanobu Enomoto
Session: e-Poster Display Session
90P - The role of miR-133a-3p/SP1/IGF1R axis in the progression of colorectal cancer
Presenter: Hui Li
Session: e-Poster Display Session
91P - Prognostic biomarker of clinical outcome in locally advanced rectal cancer in Chinese patients
Presenter: Sandy Ho
Session: e-Poster Display Session
92P - Development and validation of risk and prognostic nomograms for bone metastases in advanced colorectal cancer patients
Presenter: Nan Wang
Session: e-Poster Display Session
93P - Assessment of nutritional status of colorectal cancer patients in a tertiary government hospital
Presenter: Rogelio Velasco
Session: e-Poster Display Session